BC-1215

製品コードS0322 バッチS032201

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
化学式

C26H26N4
分子量 394.51 CAS No. 1507370-20-8
Solubility (25°C)* 体外 DMSO 79 mg/mL (200.24 mM)
Ethanol 79 mg/mL (200.24 mM)
Water Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 BC-1215 is an inhibitor of F-box protein 3 (Fbxo3, a ubiquitin E3 ligase component) with IC50 of 0.9 μg/mL and LC50 of 87 μg/ml for IL-1β release. BC-1215 inhibits the Fbxo3-TRAF activation pathway by destabilizing TRAF1-6.
in vitro

BC-1215, a Fbxo3 inhibitor, inhibits the Fbxo3-TRAF activation pathway by destabilizing TRAF1-6 proteins. Also, this compound inhibits LPS-induced secretion of a broad spectrum of TH1 panel cytokines in human PBMC.[1]
in vivo

A small molecule Fbxo3 inhibitor, BC-1215, reduces inflammation by antagonizing actions of this compound on TRAF–cytokine signaling.[1]

プロトコル(参考用のみ)

細胞アッセイ 細胞株 Murine lung epithelial (MLE) cells, PBMC, U937 cells
濃度 --
反応時間 --
実験の流れ

Murine lung epithelial (MLE) cells were treated with benzathine or BC-1215 at different concentrations for 16 h. Cells were collected and assayed for TRAF1-6, Fbxl2, Fbxo3, and actin immunoblotting. PBMC were treated with either vehicle or 2 μg/ml LPS for 18 h, some cells were also co-treated with this compound in a dose dependent manner up to 10 μg/ml. 18 h later, cells were collected and processed for TRAF immunoblots. U937 cells were transfected with either empty or Fbxo3 plasmid for 24 h. Cells were also treated with this chemical in a dose dependent manner up to 10 μg/ml. 18 h later, cells were collected and processed for TRAF immunoblots. PBMC (0.6 ml at 1.5 x 106/ml) were treated with 2 ug/ml LPS for 16 h with this compound at 10 μg/ml. Cytokine release was monitored by the human cytokine array.
動物実験 動物モデル model of a cecal ligation and puncture (CLP)-induced sepsis
投薬量 100 μg
投与方法 i.p.

参考

  • https://pubmed.ncbi.nlm.nih.gov/23542741/

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。